Aldeyra Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 10
- Market Cap
- $319M
- Website
- http://www.aldeyra.com
- Introduction
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT05234554
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05102409
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 361
- Registration Number
- NCT05062330
- Locations
- 🇺🇸
Andover Eye Associates (Raynham), Raynham, Massachusetts, United States
A Clinical Trial to Assess Subjects With Dry Eye Disease.
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: Vehicle Ophthalmic SolutionDrug: Reproxalap Ophthalmic Solution (0.25%)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT04971031
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
Phase 2
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: ADX-629
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04908514
- Locations
- 🇺🇸
TCR Medical Corporation, San Diego, California, United States
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.
Phase 2
Completed
- Conditions
- Covid19
- Interventions
- Drug: ADX-629Drug: Placebo
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04847544
- Locations
- 🇺🇸
Medical Research Center of Miami II, Inc., Miami, Florida, United States
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Placebo Comparator
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 757
- Registration Number
- NCT04735393
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)
Phase 2
Completed
- Conditions
- Atopic Asthma
- Interventions
- Drug: ADX-629Drug: Placebo
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04728711
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry EyeDry Eye Syndromes
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Opthalmic Solution
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 331
- Registration Number
- NCT04674358
- Locations
- 🇺🇸
University Clinical Health, Memphis, Tennessee, United States
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Reproxalap Ophthalmic Solution (0.25%)Drug: Vehicle Ophthalmic Solution
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Aldeyra Therapeutics, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT04207736
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath